A clinical study to evaluate NPX372- a new drug candidate targeting B7-H7 in Solid Tumors
Latest Information Update: 10 Sep 2024
Price :
$35 *
At a glance
- Drugs NPX 372 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 10 Sep 2024 New trial record
- 05 Sep 2024 According to NextPoint Therapeutics media release, the company is rapidly advancing the Investigational New Drug (IND) application for NPX372.